Abstract:Introduction: Cooling protects against cardiac ischemia/reperfusion (I/R) injury by enhancing PI3K/Akt/NOS signaling. PI3K/Akt signaling depends on binding by its regulatory subunit p85 to the catalytic subunit p110 or the inhibitory phosphatase PTEN. We studied novel TAT-p85 fusion proteins that selectively inhibit these competing p85 interactions. We hypothesized that TAT fused p85 lacking the PTEN binding site (TAT-ΔPTEN p85) would enhance Akt phosphorylation to afford cardioprotection in a heart cell model of I/R. Conversely, TAT fused p85 lacking the p110 binding site (TAT-Δp110p85) would abrogate protection. To further test TAT fusion proteins for the I/R injury of mouse cardiac arrest (CA), we studied whether a TAT-fused PTEN C-terminal 9 amino acid (TAT-PTEN9c) PTEN inhibitor would activate Akt in critical organs and improve survival. Methods: A TAT-Δp110 p85 plasmid was constructed with nucleotide deletions at amino acids 478-513. The TAT-ΔPTEN p85 plasmid deleted amino acids 1-313. TAT-PTEN9c was synthesized by Anaspec. Cardiomyocytes were isolated from 1-2-day old C57BL6/J mice and exposed to up to 90 min ischemic arrest with 3 h reperfusion (I/R). Cell viability was evaluated by propidium iodide uptake and p-Akt was measured by Western blot. C57BL6 mice were subjected to an established potassium-induced CA protocol. TAT-PTEN9c (7.8 mg/kg) was given IV after return of spontaneous circulation (ROSC) (n=10) and the 2nd dose for another 5 mice was given at 60 min after ROSC. Results: TAT-Δp110 p85 increased cell death from 44.6 +/- 2.7% to 92.5 +/- 3.4%, while TAT-ΔPTEN p85 decreased cell death caused by I/R from 47.8 +/- 1.4% to 11.9 +/- 5.3%. 30 mice were randomized to either saline or TAT-PTEN9c post-ROSC. TAT fusion proteins could be seen within heart and brain tissues within 2 minutes of IV infusion. The survival rate was significantly increased in TAT-PTEN9c treated mice compared with that of saline treated mice at 2 hrs (14/15, 93% vs. 9/15, 60%, P < 0.05) and at 4 hrs (10/15, 67% vs. 6/15, 40%, P < 0.05) after ROSC. Conclusions: TAT fusion protein inhibition of PTEN during cardiac I/R and after cardiac arrest appear to be promising strategies for enhancing Akt activation and survival.

In VivoDelivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects Against Ischemic Brain Injury and Neuronal Apoptosis

Bcl-2 Gene Therapy for Apoptosis Following Traumatic Brain Injury.

TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF.

[Neuroprotection of a Neotype Transactivating-Brain-derived Neurotrophic Factor Fusion Protein with Penetrating Activity of Blood-Brain Barrier].

Trans-activator of Transcription-Mediated Delivery of NEP1-40 Protein into Brain Has a Neuroprotective Effect Against Focal Cerebral Ischemic Injury Via Inhibition of Neuronal Apoptosis.

TAT-mediated Delivery of Neuroglobin Protects Against Focal Cerebral Ischemia in Mice

Neuroprotective Effect Of Tat-14-3-3 Epsilon Fusion Protein Against Cerebral Ischemia/Reperfusion Injury In Rats

Neuroprotective Effect of TAT-14-3-3ε Fusion Protein against Cerebral Ischemia/Reperfusion Injury in Rats

In vivo delivery of a XIAP (BIR3-RING) fusion protein containing the protein transduction domain protects against neuronal death induced by seizures.

Intravenous Injection of Fusion Protein TAT-BDNF Relieves Acute Spinal Cord Injury in Rats

Neuroprotection by cell permeable TAT-mGluR1 peptide in ischemia: synergy between carrier and cargo sequences.

The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia.

Engineering the protein targeting two pathways of cerebral ischemia reperfusion injury provides better neuroprotective effect than targeting one pathway

Targeted Delivery of Neurogenin-2 Protein in the Treatment for Cerebral Ischemia-Reperfusion Injury.

A sphingosine kinase 2-mimicking TAT-peptide protects neurons against ischemia-reperfusion injury by activating BNIP3-mediated mitophagy

Abstract 18534: TAT-Protein Blockade of PTEN after Cardiac Ischemia is Highly Protective

Protosappanin A Maintains Neuronal Mitochondrial Homeostasis Through Promoting Autophagic Degradation of Bax

Adeno-associated virus-mediated delivery of BCL-w gene improves outcome after transient focal cerebral ischemia

TAT Protein Transduction Domain Mediates Transmembrane Delivery of BCR/ABL Fusion Protein into Tissue Cells of Mice in Vivo

Tat-Nep1-40 As A Novel Therapeutic Candidate for Axonal Regeneration and Functional Recovery after Stroke

Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence.